The writing had been on the wall for Parp inhibitors in first-line prostate cancer, and last week’s US panel showed no mercy.
Conventional wisdom says manufacturing takes second place to clinical development, but Point turned that on its head, and now a big catalyst approaches.
Talapro-2 data backing Talzenna in all-comers are slated by Asco-GU’s discussant, as Lynparza shows precisely what might go wrong.
Talzenna scores in first-line prostate cancer irrespective of HRR status, but for now we only have Pfizer’s word for it.
A November adcom could decide whether Zejula will lose yet more ground to Lynparza.